Top

Published in:

01-07-2011 | Laboratory Investigation - Human/Animal Tissue

Expression of Gli1 and PARP1 in medulloblastoma: an immunohistochemical study of 65 cases

Authors: Joze Pizem, Mara Popovic, Andrej Cör

Published in: Journal of Neuro-Oncology | Issue 3/2011

Abstract

Activation of the sonic hedgehog (SHH) signalling pathway, which is involved in the formation of a significant proportion of medulloblastomas, is characterised by up-regulation and nuclear localisation of downstream transcription factor Gli1. Our aim was to analyse Gli1 expression by immunohistochemistry in a large group of medulloblastomas, to assess possible correlations with WNT (wingless) pathway activation and poly(ADP-ribose) polymerase-1 (PARP1) expression, previously shown to be associated with SHH pathway activation in a mouse model of medulloblastoma. We analysed expression and localisation of Gli1, β-catenin and PARP1 by immunohistochemistry in a series of 65 consecutive medulloblastomas. Gli1 was positive in 40 (61.5%) medulloblastomas, as revealed by either strong (21 cases) or mild (19 cases) nuclear reaction in more than 50% of tumour cells. Nuclear positivity for PARP1 was noted in all 65 cases, ranging from 46% to 100% (mean 80%) but was not correlated with Gli1 positivity. Gli1 was positive in 9 of 11 cases with nuclear localisation of β-catenin, signifying concurrent activation of SHH and WNT pathways. Overall survival of patients with strong nuclear reaction to Gli1 was better compared with patients with Gli1-negative medulloblastomas. Immunohistochemical detection of Gli1 could be useful in identifying medulloblastomas with SHH pathway activation. As revealed by nuclear reaction to Gli1, the SHH pathway is activated in approximately 60% of medulloblastomas. In some medulloblastomas, both SHH and WNT appear to be activated. PARP1 is highly expressed in medulloblastomas. It might be useful as a target to increase the effectiveness of current treatment modalities.

Gilbertson RJ (2004) Medulloblastoma: signalling a change in treatment. Lancet Oncol 5:209–218PubMedCrossRef

Ferretti E, De Smaele E, Di Marcotullio L, Screpanti I, Gulino A (2005) Hedgehog checkpoints in medulloblastoma: the chromosome 17p deletion paradigm. Trends Mol Med 11:537–545PubMedCrossRef

Yoon JW, Gilbertson R, Iannoccone S, Walterhouse D (2009) Defining a role for sonic hedgehog pathway activation in desmoplastic medulloblastoma by identifying Gli1 target genes. Int J Cancer 124:109–119PubMedCrossRef

Toftgard R (2000) Hedgehog signalling in cancer. Cell Mol Life Sci 57:1720–1731PubMedCrossRef

Cohen MM Jr (2003) The hedgehog signaling network. Am J Med Genet 123A:5–28PubMedCrossRef

Di Marcotullio L, Ferretti E, De Smaele E, Argenti B, Mincione C, Zazzeroni F, Gallo R, Masuelli L, Napolitano M, Maroder M, Modesti A, Giangaspero F, Screpanti I, Allesse E, Gulino A (2004) REN^KCTD11 is a suppressor of hedgehog signalling and is deleted in human medulloblastoma. Proc Natl Acad Sci USA 29:10833–10838CrossRef

Bar EE, Stearns D (2008) New developments in medulloblastoma treatment: the potential of a cyclopamine-lovastatin combination. Expert Opin Investig Drugs 17:185–195PubMedCrossRef

Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, Russell TL, Ellenbogen RG, Bernstein ID, Beachy PA, Olson JM (2004) The SmoA1 mouse model reveals that Notch signalling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 64:7794–7800PubMedCrossRef

Argenti B, Gallo R, Di Marcotullio L, Ferretti E, Napolitano M, Canterini S, De Smaele E, Greco A, Fiorenza MT, Screpanti I, Alesse E, Gulino A (2005) Hedgehog antagonist REN^KCTD11 regulates proliferation and apoptosis in developing granule cell progenitors. J Neurosci 25:8338–8346PubMedCrossRef

10.

Yoon JW, Kita Y, Frank DJ, Majewski RR, Konicek BA, Nobrega MA, Jacob H, Walterhouse D, Iannaccone P (2002) Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 277:5548–5555PubMedCrossRef

11.

Bar EE, Chaudhry A, Farah MH, Eberhart CG (2007) Hedgehog signalling promotes medulloblastoma survival via BclII. Am J Pathol 170:347–355PubMedCrossRef

12.

Romer J, Curran T (2005) Targeting medulloblastoma: small-molecule inhibitors of the sonic hedgehog pathway as potential cancer therapeutics. Cancer Res 65:4975–4978PubMedCrossRef

13.

Taylor MD, Zhang X, Liu L, Hui C-C, Mainprize TG, Scherer SW, Wainwright B, Hogg D, Rutka JT (2004) Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling. Oncogene 43:4577–4583CrossRef

14.

Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, van Schouten-Meeteren N, Caron HN, Cloos J, Mrsic A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 3:e3088PubMedCrossRef

15.

Thomson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24:1924–1931CrossRef

16.

Lee J, Miller HL, Jehnsen P, Hernan R, Connelly M, Wetmore C, Zindy F, Roussel MF, Curran T, Gilbertson RJ, McKinnon PJ (2003) A molecular fingerprint of medulloblastoma. Cancer Res 63:5428–5437PubMed

17.

Tong W-M, Ohgaki H, Huang H, Granier C, Kleihues P, Wang Z-Q (2003) Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastoma in p53^−/− mice. Am J Pathol 162:343–352PubMedCrossRef

18.

Tanori M, Mancuso M, Pasuali E, Leonardi S, Rebessi S, Di Majo V, Guilly M-N, Giangaspero F, Covelli V, Pazzaglia S, Saran A (2008) PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma. Carcinogenesis 29:1911–1919PubMedCrossRef

19.

Tong W-M, Cortes U, Wang Z-Q (2001) Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta 1552:27–37PubMed

20.

Eberhart CG (2003) Medulloblastoma in mice lacking p53 and PARP. All roads lead to Gli. Am J Pathol 162:7–9PubMedCrossRef

21.

Giangaspero F, Eberhart CG, Haapasalo H, Pietsch T, Wiestler OD, Ellison DW (2007) Medulloblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) World Health Organisation Classification of Tumours: WHO Classification of Tumours of the Central Nervous System. IARC Press, Lyon, pp 132–140

22.

Min HS, Lee YJ, Park K, Cho B-K, Park S-H (2006) Medulloblastoma: histologic and molecular markers of anaplasia and biologic behavior. Acta Neuropathol 112:13–20PubMedCrossRef

23.

Rodriguez FJ, Eberhart C, O’Neill BP, Slezak J, Burger PC, Goldthwaite P, Wu W, Giannini C (2007) Histopathologic grading of adult medulloblastoma. Cancer 109:2557–2565PubMedCrossRef

24.

Eberhart CG, Kepner JL, Goldtwhwaite PT, Kun LE, Duffner PK, Friedman HS, Strother DR, Burger PC (2002) Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 94:552–560PubMedCrossRef

25.

Pizem J, Cör A, Zadravec-Zaletel L, Popovic M (2005) Survivin is a negative prognostic marker in medulloblastoma. Neuropathol Appl Neurobiol 31:422–428PubMedCrossRef

26.

Eberhart CG, Tihan T, Burger PC (2000) Nuclear localisation of β-catenin in medulloblastomas. J Neuropathol Exp Neurol 59:333–337PubMed

27.

Pizem J, Cör A, Zadravec-Zaletel L, Popovic M (2005) Prognostic significance of apoptosis in medulloblastoma. Neurosci Lett 331:69–73CrossRef

28.

Epstein EH (2008) Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 8:743–754PubMedCrossRef

29.

Marino S (2005) Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 11:17–22PubMedCrossRef

30.

Jung HL, Wang K-C, Kim S-K, Sung KW, Koo HK, Shin HY, Ahn HS, Shin HJ, Cho B-K (2004) Loss of heterozygosity analysis of chromosome 17p13.1-13.3 and its correlation with clinical outcome in medulloblastomas. J Neurooncol 67:41–46PubMedCrossRef

31.

Yanai K, Nagai S, Wada J, Yamanaka N, Nakamura M, Torata N, Noshiro H, Tsuneyoshi M, Tanaka M, Katano M (2007) Hedgehog signalling pathway is a possible therapeutic target for gastric cancer. J Surg Oncol 95:55–62PubMedCrossRef

32.

Vestergaard J, Pedersen MW, Pedersen N, Ensinger C, Tümer Z, Tommerup N, Poulsen HS, Larsen LA (2006) Hedgehog signaling in small-cell lung cancer: frequent in vivo but rare event in vitro. Lung Cancer 52:281–290PubMedCrossRef

33.

Zhang L, Chen X-M, Sun Z-J, Bian Z, Fan M-W, Chen Z (2006) Epithelial expression of SHH signaling pathway in odontogenic tumors. Oral Oncol 42:398–408PubMedCrossRef

34.

Satoh K, Kanno A, Hamada S, Hirota M, Umino J, Masamune A, Egawa S, Motoi F, Unno M, Shimosegawa T (2008) Expression of sonic hedgehog signalling pathway correlates with tumorigenesis of intraductal papillary mucinous neoplasm of the pancreas. Oncol Rep 19:1185–1190PubMed

35.

Ghali L, Wong ST, Green J, Tidman N, Quinn AG (1999) Gli1 protein is expressed in basal cell carcinomas, outer root sheath keratinocytes and a subpopulation of mesenchymal cells in normal human skin. J Investig Dermatol 113:595–599PubMedCrossRef

36.

Feng YZ, Shiozawa T, Miyamoto T, Kashima H, Kurai M, Suzuki A, Ying-Song J, Konishi I (2007) Overexpression of hedgehog signaling molecules and its involvement in the proliferation of endometrial carcinoma cells. Clin Cancer Res 13:1389–1398PubMedCrossRef

37.

Concoran RB, Scott MP (2001) A mouse model for medulloblastoma and basal cell nevus syndrome. J Neurooncol 53:307–318CrossRef

38.

Brustmann H (2007) Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissue. Pathol Res Pract 203:65–72PubMedCrossRef

39.

Nosho K, Yamamoto H, Mikami M, Taniguchi H, Takahashi T, Adachi Y, Imamura A, Imai K, Shinomura Y (2006) Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer 42:2374–2381PubMedCrossRef

40.

Staibano S, Pepe S, Lo Muzio L, Somma P, Mascolo M, Argenziano G, Scalvenzi M, Slvatore G, Fabbrocini G, Molea G, Bianco AR, Carlomagno C, De Rosa G (2005) Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 36:724–731PubMedCrossRef

41.

Brustman H (2007) Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1 and outcome. Int J Gynecol Pathol 26:147–153CrossRef

42.

Barton VN, Donson AM, Kleinschmidt-DeMasters BK, Gore L, Liu AK, Foreman NK (2009) PARP1 expression in pediatric central nervous system tumors. Pediatr Blood Cancer 53:1227–1230PubMedCrossRef

43.

Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, Bouffet E, Hawkins C (2010) Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor α and poly(ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 28:1337–1344PubMedCrossRef

44.

Lord CJ, Ashworth A (2008) Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 8:363–368PubMedCrossRef

45.

Tentori L, Muzi A, Dorio AS, Bultrini S, Mazzon E, Lacal PM, Shah GM, Zhang J, Navarra P, Nocentini G, Cuzzocrea S, Graziani G (2008) Stable depletion of poly(ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur J Cancer 44:1304–1314CrossRef

46.

Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC (2005) β-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. J Clin Oncol 23:7951–7957PubMedCrossRef

47.

Carlotti CG Jr, Smith C, Rutka JT (2008) The molecular genetics of medulloblastoma: an assessment of new therapeutic targets. Neurosurg Rev 31:359–369PubMedCrossRef

48.

Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, Agatep R, Chiappa S, Gao L, Lowrance A, Hao A, Goldstein AM, Stavrou T, Scherer SW, Dura WT, Wainwright B, Squire JA, Rutka JT, Hogg D (2002) Mutations in SUFU predispose to medulloblastoma. Nat Genet 31:306–310PubMedCrossRef

49.

Koch A, Waha A, Tonn JC, Sörensen N, Berthold F, Wolter M, Reifenberger J, Hartmann W, Friedl W, Reifenberger G, Wiestler OD, Pietsch T (2001) Somatic mutations of WNT/WINGLESS signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 93:445–449PubMedCrossRef

50.

Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A (2008) Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 14:971–976PubMedCrossRef

Title: Expression of Gli1 and PARP1 in medulloblastoma: an immunohistochemical study of 65 cases
Authors: Joze Pizem
Mara Popovic
Andrej Cör
Publication date: 01-07-2011
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2011
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-010-0431-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expression of Gli1 and PARP1 in medulloblastoma: an immunohistochemical study of 65 cases

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Malignant transformation of craniopharyngioma: case report and review of the literature

Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma

Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma

Cognitive effects of tumour and surgical treatment in glioma patients

Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival

Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors